Table 5 Sensitivity analysis 2 for the relationships between both the eGFR at age 88 years and the decrease in the eGFR 3 years before (between age 85 and 88) and total and cardiovascular (CV) mortality
eGFR slope per year between 85 and 88 years in ml/min/1.73 m²/year | |||||
|---|---|---|---|---|---|
>-1 | -1 to -2.99 | -3 to -4.99 | <-5 | ||
eGFR at age 88 > 60 (n=169) | n=128 | n=26 | n=12 | n=3 | |
Overall mortality | 1 (ref) | 1.44 (0.85-2.44) | 2.77 (1.35-5.68) | 4.41 (1.27-15.33) | |
CV mortality | 1 (ref) | 1.32 (0.48-3.67) | 4.08 (1.39-11.96) | 10.35 (2.46-43.61) | |
eGFR at age 88 45-59 (n=147) | n=71 | n=46 | n=21 | n=9 | |
Overall mortality | 1 (ref) | 0.89 (0.53-1.52) | 1.58 (0.84-2.96) | 3.37 (1.51-7.52) | |
CV mortality | 1 (ref) | 0.95 (0.38-2.37) | 0.83 (0.22-3.09) | 4.41 (1.24-15.78) | |
eGFR at age 88 < 45 (n=62) | n=20 | n=21 | n=14 | n=7 | |
Overall mortality | 1 (ref) | 0.74 (0.36-1.51) | 0.50 (0.17-1.46) | 2.26 (0.64-8.03) | |
CV mortality | 1 (ref) | 0.97 (0.37-2.54) | 0.29 (0.04-2.32) | 4.04 (1.01-16.20) | |